Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AnaptysBio, Inc.
Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance
US FDA meeting directs attention to the vitiligo patient experience as a small group of potential treatments, led by topical Janus kinase inhibitors, are at the Phase II hinge point.
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
Topline data from a Phase II proof-of-concept study evaluating anti-IL-33 monotherapy REGN3500 (SAR440340) in asthma suggest it is not as effective as Dupixent and that there is no incremental benefit from adding it to Dupixent.
Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.
- Large Molecule